Urinary sulphated glycosaminoglycans excretion in obese patients with type 2 diabetes mellitus treated with metformin

References

• Araki, E. and Nishikawa, T., 2010. Oxidative stress: a cause and therapeutic target of diabetic complications. Journal of diabetes investigation, 1 (3), 90–96.
   PubMed Web of Science ®Google Scholar
• Aso, Y., et al., 2004. Dissociation between urinary pyrraline and pentosidine concentrations in diabetic patients with advanced nephropathy. Journal of laboratory and clinical medicine, 144 (2), 92–99.
   PubMed Web of Science ®Google Scholar
• Bergmann, K. and Sypniewska, G., 2013. Diabetes as a complication of adipose tissue dysfunction. Is there a role for potential new biomarkers? Clinical chemistry and laboratory medicine, 51 (1), 177–185.
   PubMed Web of Science ®Google Scholar
• Cameron, A.R., et al., 2016. Anti-inflammatory effects of metformin irrespective of diabetes status. Circulation research, 119 (5), 652–665.
   PubMed Web of Science ®Google Scholar
• Czupryniak, L., 2017. 2017 Polish Diabetological Association Guidelines on Clinical Diabetes Care and what every GP should know about them. Lekarz POZ, 3 (2), 93–97.
   Google Scholar
• Dong, Q.Y., et al., 2008. Urinary 8-hydroxydeoxyguanosine levels in diabetic retinopathy patients. European journal of ophthalmology, 18 (1), 94–98.
   PubMed Web of Science ®Google Scholar
• Edwards, I.J., et al., 2004. Arterial heparan sulfate is negatively associated with hyperglycemia and atherosclerosis in diabetic monkeys. Cardiovascular diabetology, 3 (1), 6.
   PubMedGoogle Scholar
• Elbert, A.E., et al., 2000. Urinary heparan sulphate is increased in normoalbuminuric diabetic patients. Medicina (B Aires), 60 (2), 195–201.
   PubMed Web of Science ®Google Scholar
• Esteghamati, A., et al., 2013. Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: a randomized clinical trial. Clinical nutrition, 32 (2), 179–185.
   PubMed Web of Science ®Google Scholar
• Gowd, V., Gurukar, A., and Chilkunda, N.D., 2016. Glycosaminoglycan remodelling during diabetes and the role of dietary factors in their modulation. World journal of diabetes, 7 (4), 67–73.
   PubMed Web of Science ®Google Scholar
• Han, J., et al., 2009. Changes in cultured endothelial cell glycosaminoglycans under hyperglycemic conditions and the effect of insulin and heparin. Cardiovascular diabetology, 8 (1), 46.
   PubMedGoogle Scholar
• Jan, J.S., et al., 2017. The novel HDAC8 inhibitor WK2-16 attenuates lipopolysaccharide-activated matrix metalloproteinase-9 expression in human monocytic cells and improves hypercytokinemia in vivo. International journal of molecular sciences, 18 (7), 1394.
   Web of Science ®Google Scholar
• Jura-Półtorak, A., et al., 2014. Alteration of plasma glycosaminoglycans profile in patients with rheumatoid arthritis in relation to disease activity. Clinica chimica acta, 433, 20–27.
   PubMed Web of Science ®Google Scholar
• Juretić, D., Krajnović, V., and Lukač-Bajalo, J., 2002. Altered distribution of urinary glycosaminoglycans in diabetic subjects. Acta diabetologica, 39 (3), 123–128.
   PubMed Web of Science ®Google Scholar
• Kanazawa, I., et al., 2011. Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus. Experimental and clinical endocrinology & diabetes, 119 (06), 362–365.
   PubMedGoogle Scholar
• Kim, J., et al., 2012. Renal podocyte injury in a rat model of type 2 diabetes is prevented by metformin. Experimental diabetes research, 2012, 1.
   Google Scholar
• Kolset, S.O., Reinholt, F.P., and Jenssen, T., 2012. Diabetic nephropathy and extracellular matrix. Journal of histochemistry & cytochemistry, 60 (12), 976–986.
   PubMed Web of Science ®Google Scholar
• Komosińska-Vassev, K., et al., 2005. Alterations of glycosaminoglycan metabolism in the development of diabetic complications in relation to metabolic control. Clinical chemistry and laboratory medicine, 43 (9), 924–929.
   PubMed Web of Science ®Google Scholar
• Komosińska-Vassev, K., et al., 2012. Age- and gender-related alteration in plasma advanced oxidation protein products (AOPP) and glycosaminoglycan (GAG) concentrations in physiological ageing. Clinical chemistry and laboratory medicine, 50 (3), 557–563.
   PubMed Web of Science ®Google Scholar
• Komosińska-Vassev, K., et al., 2014. Urinary glycosaminoglycans (uGAG) excretion in health pediatric and adolescent population. Clinical biochemistry, 47 (13–14), 1341–1343.
   PubMed Web of Science ®Google Scholar
• Leppeda, A.J., et al., 2017. Significance of urinary glycosaminoglycans/proteoglycans in the evaluation of type 1 and type 2 diabetes complications. Journal diabetes and its complications, 31 (1), 149–155.
   PubMed Web of Science ®Google Scholar
• Mathenson, A., et al., 2010. Urinary biomarkers involved in type 2 diabetes: a review. Diabetes metabolism research and reviews, 26, 150–171.
   PubMed Web of Science ®Google Scholar
• Nishikawa, T., et al., 2003. Evaluation of urinary 8-hydroxydeoxy-guanosine as a novel biomarker of macrovascular complications in type 2 diabetes. Diabetes care, 26 (5), 1507–1512.
   PubMed Web of Science ®Google Scholar
• Olczyk, P., et al., 2017. Adiponectin, leptin, and leptin receptor in obese patients with type 2 diabetes treated with insulin detemir. Molecules, 22 (8), 1274.
   Web of Science ®Google Scholar
• Pavlović, D., et al., 2000. Effect of four-week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes. Diabetes, obesity & metabolism, 2 (4), 251–256.
   PubMed Web of Science ®Google Scholar
• Popławska-Kita, A., et al., 2008. Glycosaminoglycans urinary excretion as a marker of the early stages of diabetic nephropathy and the disease progression. Diabetes/metabolism research and reviews, 24 (4), 310–317.
   PubMed Web of Science ®Google Scholar
• Rops, A.L., et al., 2012. Urinary heparanase activity in patients with type 1 and type 2 diabetes. Nephrology dialysis transplantation, 27 (7), 2853–2861.
   PubMed Web of Science ®Google Scholar
• Shafat, I., et al., 2011. Heparanase levels are elevated in the urine and plasma of type 2 diabetes patients and associated with blood glucose levels. Plos one, 6 (2), e17312.
   PubMed Web of Science ®Google Scholar
• Szeremeta, A., et al., 2018. Effects of a 15-month anti-TNF-α treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis. Arthritis research & therapy, 20 (1), 211.
   PubMedGoogle Scholar
• Zhao, T., et al., 2013. Diabetes results in structural alteration of chondroitin sulfate in the urine. Journal of pharmacy & pharmaceutical sciences, 16 (3), 486–493.
   PubMed Web of Science ®Google Scholar